Biomarkers in Development of Psychotropic Drugs

Overview

Journal Dialogues Clin Neurosci

Specialty Neurology

Date 2011 Aug 17

PMID 21842620

Citations 12

Authors

K Wiedemann

Affiliations

Soon will be listed here.

Abstract

Biomarkers have been receiving increasing attention, especially in the field of psychiatry In contrast to the availability of potent therapeutic tools including pharmacotherapy, psychotherapy, and biological therapies, unmet needs remain in terms of onset of action, stability of response, and further improvement of the clinical course. Biomarkers are objectively measured characteristics which serve as indicators of the causes of illnesses, their clinical course, and modification by treatment. There exist a variety of markers: laboratory markers which comprise the determination of genetic and epigenetic markers, neurotransmitters, hormones, cytokines, neuropeptides, enzymes, and others as single measures; electrophysiological markers which usually comprise electroencephalography (EEG) measures, and in particular sleep EEG and evoked potentials, magnetic encephalography, electrocardiogram, facial electromyography, skin conductance, and others; brain imaging techniques such as cranial computed tomography, magnetic resonance imaging, functional MRI, magnetic resonance spectroscopy, positron emission tomography, and single photon emission computed tomography; and behavioral approaches such as cue exposure and challenge tests which can be used to induce especially emotional processes in anxiety and depression. Examples for each of these domains are provided in this review. With a view to developing more individually tailored therapeutic strategies, the characterization of patients and the courses of different types of treatment will become even more important in the future.

Citing Articles

Exploring the Relationships Between Antipsychotic Dosage and Voice Characteristics in Relation to Extrapyramidal Symptoms.

Kim H, Kim S, Lee S, Lee K, Kim E Psychiatry Investig. 2024; 21(8):822-831.

PMID: 39111750 PMC: 11321868. DOI: 10.30773/pi.2023.0417.

A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.

Krystal A, Pizzagalli D, Smoski M, Mathew S, Nurnberger Jr J, Lisanby S Nat Med. 2020; 26(5):760-768.

PMID: 32231295 PMC: 9949770. DOI: 10.1038/s41591-020-0806-7.

Sex differences in resilience: Experiential factors and their mechanisms.

Fallon I, Tanner M, Greenwood B, Baratta M Eur J Neurosci. 2019; 52(1):2530-2547.

PMID: 31800125 PMC: 7269860. DOI: 10.1111/ejn.14639.

The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development.

Krystal A, Pizzagalli D, Mathew S, Sanacora G, Keefe R, Song A Nat Rev Drug Discov. 2018; 18(1):82-84.

PMID: 30591715 PMC: 6816017. DOI: 10.1038/nrd.2018.222.

Pharmaco fMRI: Determining the functional anatomy of the effects of medication.

Wandschneider B, Koepp M Neuroimage Clin. 2016; 12:691-697.

PMID: 27766202 PMC: 5067101. DOI: 10.1016/j.nicl.2016.10.002.

References

Filiou M, Turck C, Martins-de-Souza D . Quantitative proteomics for investigating psychiatric disorders. Proteomics Clin Appl. 2011; 5(1-2):38-49. DOI: 10.1002/prca.201000060. View

Frank R, Hargreaves R . Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov. 2003; 2(7):566-80. DOI: 10.1038/nrd1130. View

Fleeman N, Dundar Y, Dickson R, Jorgensen A, Pushpakom S, McLeod C . Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J. 2010; 11(1):1-14. DOI: 10.1038/tpj.2010.73. View

Laje G, Perlis R, Rush A, McMahon F . Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatr Serv. 2009; 60(11):1446-57. PMC: 3775610. DOI: 10.1176/appi.ps.60.11.1446. View

Demiralay C, Jahn H, Kellner M, Yassouridis A, Wiedemann K . Influence of exogenous atrial natriuretic peptide on the nocturnal hypothalamic-pituitary-adrenal axis and sleep in healthy men. Psychoneuroendocrinology. 2010; 35(10):1438-45. DOI: 10.1016/j.psyneuen.2010.04.009. View

Fergusson D, Horwood L, Miller A, Kennedy M . Life stress, 5-HTTLPR and mental disorder: findings from a 30-year longitudinal study. Br J Psychiatry. 2011; 198(2):129-35. PMC: 3031653. DOI: 10.1192/bjp.bp.110.085993. View

Ising M, Kunzel H, Binder E, Nickel T, Modell S, Holsboer F . The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29(6):1085-93. DOI: 10.1016/j.pnpbp.2005.03.014. View

Hinkelmann K, Yassouridis A, Mass R, Tenge H, Kellner M, Jahn H . CCK-4: Psychophysiological conditioning elicits features of spontaneous panic attacks. J Psychiatr Res. 2010; 44(16):1148-53. DOI: 10.1016/j.jpsychires.2010.04.004. View

Lesko L, Atkinson Jr A . Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol. 2001; 41:347-66. DOI: 10.1146/annurev.pharmtox.41.1.347. View

10.

Leiser S, Dunlop J, Bowlby M, Devilbiss D . Aligning strategies for using EEG as a surrogate biomarker: a review of preclinical and clinical research. Biochem Pharmacol. 2010; 81(12):1408-21. DOI: 10.1016/j.bcp.2010.10.002. View

11.

Steiger A, Kimura M . Wake and sleep EEG provide biomarkers in depression. J Psychiatr Res. 2009; 44(4):242-52. DOI: 10.1016/j.jpsychires.2009.08.013. View

12.

Risch N, Herrell R, Lehner T, Liang K, Eaves L, Hoh J . Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA. 2009; 301(23):2462-71. PMC: 2938776. DOI: 10.1001/jama.2009.878. View

13.

Schule C, Baghai T, Eser D, Hafner S, Born C, Herrmann S . The combined dexamethasone/CRH Test (DEX/CRH test) and prediction of acute treatment response in major depression. PLoS One. 2009; 4(1):e4324. PMC: 2629564. DOI: 10.1371/journal.pone.0004324. View

14.

Seier F, Kellner M, Yassouridis A, Heese R, STRIAN F, Wiedemann K . Autonomic reactivity and hormonal secretion in lactate-induced panic attacks. Am J Physiol. 1997; 272(6 Pt 2):H2630-8. DOI: 10.1152/ajpheart.1997.272.6.H2630. View

15.

van Megen H, Westenberg H, den Boer J, Slaap B, Pande A . The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients. Psychopharmacology (Berl). 1997; 129(3):243-8. DOI: 10.1007/s002130050186. View

16.

McMahon F, Buervenich S, Charney D, Lipsky R, Rush A, Wilson A . Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006; 78(5):804-814. PMC: 1474035. DOI: 10.1086/503820. View

17.

Ising M, Lucae S, Binder E, Bettecken T, Uhr M, Ripke S . A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry. 2009; 66(9):966-975. PMC: 4465570. DOI: 10.1001/archgenpsychiatry.2009.95. View

18.

Gong Q, Wu Q, Scarpazza C, Lui S, Jia Z, Marquand A . Prognostic prediction of therapeutic response in depression using high-field MR imaging. Neuroimage. 2010; 55(4):1497-503. DOI: 10.1016/j.neuroimage.2010.11.079. View

19.

Zwanzger P, Eser D, Aicher S, Schule C, Baghai T, Padberg F . Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study. Neuropsychopharmacology. 2003; 28(5):979-84. DOI: 10.1038/sj.npp.1300131. View

20.

Locatelli V, Bresciani E, Tamiazzo L, Torsello A . Central nervous system-acting drugs influencing hypothalamic-pituitary-adrenal axis function. Endocr Dev. 2009; 17:108-120. DOI: 10.1159/000262533. View